Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Uterine Fibroid Treatment Drugs Market

Uterine Fibroid Treatment Drugs Market Share

Report ID: GMI6506
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Uterine Fibroid Treatment Drugs Market Share

The key players in the uterine fibroid treatment drugs market are

Pfizer Inc.
Abbvie, Inc.
AstraZeneca plc
Bayer AG
Myovant Sciences Gmbh
Ferring B.V.
Amring Pharmaceuticals Inc.
Theramex and Watson Pharma, Inc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Uterine fibroid treatment drugs industry size reached USD 1.7 billion in 2022 and will witness 10% CAGR through 2032 due to the emergence of novel medications for individuals with uterine fibroids.

Progestin-releasing intrauterine device (IUD) & contraceptives segment registered 65.7% share in 2022 on account of its advantages in managing the uterine fibroids.

North America uterine fibroid treatment drugs industry will witness 9.4% CAGR through 2023-2032 owing to the increasing demand for non-invasive, safe, and effective treatment options in the region.

Pfizer Inc., Abbvie, Inc., AstraZeneca plc, Bayer AG, Myovant Sciences Gmbh, Ferring B.V., Amring Pharmaceuticals Inc., Theramex and Watson Pharma, Inc. are some of the major uterine fibroid treatment drug companies worldwide.